ERBB2 and non-small cell lung carcinoma: Instead, DF1001 is the first-in-class, Tri-specific, Natural Kille (NK) cell Engager Therapy (TriNKET) which uses HER2 as an anchor to modulate innate and adaptive immunity, and it is being studied in phase I/II in all solid tumours, including NSCLC with HER2 alteration (MUT, AMP, and OE) (NCT04143711).